Silvia Taralli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3216918/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1623-1629.	3.3	6
2	The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review. Journal of Clinical Medicine, 2022, 11, 33.	1.0	4
3	Automated detection and classification of tumor histotypes on dynamic PET imaging data through machine-learning driven voxel classification. Computers in Biology and Medicine, 2022, 145, 105423.	3.9	11
4	Adenoid cystic carcinoma of the parotid gland: a first case report on ¹¹ C-methionine PET/CT detection of histologically confirmed pulmonary metastases. Acta Oncológica, 2022, 61, 669-671.	0.8	1
5	Diagnostic role of 11C-methionine PET/CT in patients with multiple myeloma and other plasma cell malignancy: a literature review. Clinical and Translational Imaging, 2021, 9, 3-17.	1.1	1
6	Application of Artificial Neural Network to Preoperative 18F-FDG PET/CT for Predicting Pathological Nodal Involvement in Non-small-cell Lung Cancer Patients. Frontiers in Medicine, 2021, 8, 664529.	1.2	4
7	Bone Marrow Activation After Chemotherapy Presenting as Diffuse Skeletal Uptake on 18F-Fluorocholine PET/CT. Clinical Nuclear Medicine, 2021, 46, e498-e500.	0.7	1
8	Dynamic 11C-Methionine PET-CT: Prognostic Factors for Disease Progression and Survival in Patients with Suspected Glioma Recurrence. Cancers, 2021, 13, 4777.	1.7	5
9	Short 2-[18F]Fluoro-2-Deoxy-D-Glucose PET Dynamic Acquisition Protocol to Evaluate the Influx Rate Constant by Regional Patlak Graphical Analysis in Patients With Non-Small-Cell Lung Cancer. Frontiers in Medicine, 2021, 8, 725387.	1.2	3
10	A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer. Cancers, 2020, 12, 2016.	1.7	6
11	Atypical Presentation of COVID-19 Incidentally Detected at 18F-FDG PET/CT in an Asymptomatic Oncological Patient. Clinical Nuclear Medicine, 2020, 45, e383-e385.	0.7	12
12	Which Is the Optimal Scan Time of 18F-DOPA PET/CT in Patients With Recurrent Medullary Thyroid Carcinoma?. Clinical Nuclear Medicine, 2020, 45, e134-e140.	0.7	9
13	Radiolabelled Trastuzumab PET/CT imaging: a promising non-invasive tool for the in vivo assessment of HER2 status in breast cancer patients. Clinical and Translational Imaging, 2020, 8, 95-105.	1.1	2
14	Comparison between 18F-FDG and 18F-NaF PET imaging for assessing bone metastases in breast cancer patients: a literature review. Clinical and Translational Imaging, 2020, 8, 65-78.	1.1	5
15	Is 18F-fluorodeoxyglucose positron emission tomography/computed tomography useful to discriminate metachronous lung cancer from metastasis in patients with oncological history?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 291-298.	0.4	3
16	How Often Do We Fail to Classify the Treatment Response with [18F]FDG PET/CT Acquired on Different Scanners? Data from Clinical Oncological Practice Using an Automatic Tool for SUV Harmonization. Molecular Imaging and Biology, 2019, 21, 1210-1219.	1.3	6
17	Response evaluation with 18F-FDG PET/CT in metastatic breast cancer patients treated with Palbociclib: first experience in clinical practice. Annals of Nuclear Medicine, 2019, 33, 193-200.	1.2	16
18	18F-FDG PET/CT diagnostic performance in solitary and multiple pulmonary nodules detected in patients with previous cancer history: reports of 182 nodules. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 429-436.	3.3	17

Silvia Taralli

#	Article	IF	CITATIONS
19	SUN-LB076 Potential Role of Gallium-68-Peptides and Fluorine-18-FDG PET/CT and Ki67 in Patients with Post-Surgical Residual Pituitary Adenoma. Journal of the Endocrine Society, 2019, 3, .	0.1	0
20	18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study. EJNMMI Research, 2018, 8, 64.	1.1	28
21	Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1507-1511.	1.3	10
22	Diagnostic Performance of 18F-Fluorodeoxyglucose in 162 Small Pulmonary Nodules Incidentally Detected in Subjects Without a History ofAMalignancy. Annals of Thoracic Surgery, 2016, 101, 1303-1309.	0.7	10
23	Physiological Activity of Spinal Cord in Children. Spine, 2015, 40, E647-E652.	1.0	16
24	A Rare Case of Primary Pulmonary Synovial Sarcoma in a Pediatric Patient Evaluated by 18F-FDG PET/CT. Clinical Nuclear Medicine, 2014, 39, e166-e168.	0.7	3
25	Role of PET in Cancer Diagnosis. , 2014, , 39-46.		0
26	Prevalence and malignancy risk of focal colorectal incidental uptake detected by ¹⁸ F-FDG-PET or PET/CT: a meta-analysis. Radiology and Oncology, 2014, 48, 99-104.	0.6	48
27	Usefulness of 18F-FDG PET/CT in Disease Extent and Treatment Response Assessment in a Patient With Syphilitic Aortitis. Clinical Nuclear Medicine, 2013, 38, e185-e187.	0.7	16
28	Regional Cerebral Metabolic Rate of Glucose Evaluation and Clinical Assessment in Patients With Idiopathic Normal-Pressure Hydrocephalus Before and After Ventricular Shunt Placement. Clinical Nuclear Medicine, 2013, 38, 426-431.	0.7	25
29	Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review. Radiology Research and Practice, 2012, 2012, 1-9.	0.6	42
30	A Rare Case of Synchronous Bilateral Pulmonary Neuroendocrine Tumor Detected by 68Ga-DOTANOC PET/CT. Clinical Nuclear Medicine, 2012, 37, e91-e94.	0.7	1
31	18 F-fluoro-deoxy-glucose focal uptake in very small pulmonary nodules: fact or artifact? Case reports. World Journal of Surgical Oncology, 2012, 10, 71.	0.8	5
32	Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. Annals of Nuclear Medicine, 2012, 26, 764-768.	1.2	1
33	The emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with sarcoidosis. Italian Journal of Medicine, 2012, , 21-26.	0.2	4
34	Is There a Role for Fluorine 18 Fluorodeoxyglucose-Positron Emission Tomography and Positron Emission Tomography/Computed Tomography in Evaluating Patients With Mycobacteriosis? A Systematic Review. Journal of Computer Assisted Tomography, 2011, 35, 387-393.	0.5	32
35	Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading. Clinical Nuclear Medicine, 2011, 36, 841-847.	0.7	113